ストックスクリーナーアプリを入手
26.98
3.33%
-0.9393
前日終値:
$27.92
開ける：
$27.82
24時間の取引高:
71,899
Relative Volume:
0.19
時価総額：
$1.29B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.67%
1か月 パフォーマンス:
-11.86%
6か月 パフォーマンス:
+74.13%
1年 パフォーマンス:
+89.14%
1日の値動き範囲:
$26.98
$28.41
1週間の範囲:
$25.66
$28.41
52週間の値動き範囲:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
RAPP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
26.98 | 1.33B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-09-16 | 開始されました | Truist | Buy |
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-08 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 開始されました | Jefferies | Buy |
| 2024-07-02 | 開始されました | Stifel | Buy |
| 2024-07-02 | 開始されました | TD Cowen | Buy |
すべてを表示
Rapport Therapeutics Inc (RAPP) 最新ニュース
Rapport Therapeutics, Inc. (RAPP): Investor Outlook With An 87% Potential Upside - DirectorsTalk Interviews
Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics CEO Ceesay sells $285k in shares By Investing.com - Investing.com Nigeria
Rapport Therapeutics CEO Ceesay sells $285k in shares - Investing.com
Short Interest in Rapport Therapeutics, Inc. (NASDAQ:RAPP) Expands By 20.7% - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Up 20.7% in December - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
David Bredt Sells 8,500 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - Defense World
Rapport Therapeutics (RAPP) Is Down 7.4% After Advancing RAP-219 Toward Phase 3 In Epilepsy - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Discipline and Rules-Based Execution in RAPP Response - Stock Traders Daily
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeu - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider David Bredt Sells 8,500 Shares - MarketBeat
Breakout Zone: Is Rapport Therapeutics Inc gaining market shareWeekly Stock Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Biotech With 94.53% Potential Upside - DirectorsTalk Interviews
A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219 - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%Time to Sell? - MarketBeat
FDA Phase 3 Green Light for RAP-219 Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Sahm
Will Rapport Therapeutics Inc. stock outperform growth indexesJuly 2025 Sector Moves & Safe Capital Growth Tips - Улправда
Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a Promising 84.56% Potential Upside - DirectorsTalk Interviews
Is Rapport Therapeutics Inc. stock a smart buy before Fed meeting2025 Sector Review & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
Can Rapport Therapeutics Inc. stock resist market sell offsQuarterly Portfolio Review & Risk Managed Investment Entry Signals - ulpravda.ru
Form 8-KCurrent report - ADVFN
Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff? - Yahoo Finance
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $40 to $56 - 富途牛牛
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating - TipRanks
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials - Intellectia AI
Rapport To Advance Phase 3 Program Of RAP-219 In Focal Onset Seizures In Q2 - Nasdaq
Los Angeles Daily NewsRapport Therapeutics, Inc.Common Stock (Nasdaq:RAPP) Stock Quote - FinancialContent
Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength - Yahoo Finance
Rapport Therapeutics, Inc.Common Stock (NQ: RAPP - FinancialContent
Upcoming EventsRapport Therapeutics, Inc.Common Stock (Nasdaq:RAPP) Stock Quote - FinancialContent
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 7.8%Here's Why - MarketBeat
Have Rapport Therapeutics Insiders Been Selling Stock? - simplywall.st
Form 424B5 Rapport Therapeutics, - StreetInsider
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Program - TradingView — Track All Markets
Rapport Therapeutics Advances RAP-219 into Phase 3 Trials for Focal Onset Seizures, Expands Epilepsy Portfolio with New Program - Quiver Quantitative
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline - GlobeNewswire
What technical charts say about Rapport Therapeutics Inc. stock2026 world cup usa national team qualification goalkeepers possession football odds analysis preview - ulpravda.ru
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 2,840 Shares - Defense World
Behavioral Patterns of RAPP and Institutional Flows - Stock Traders Daily
Krishnaswamy Yeleswaram Sells 2,840 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $197,338.35 in Stock - MarketBeat
Is Rapport Therapeutics Inc a good long term investmentSupport Level Holds & Free Discover Fast Growing Stocks - earlytimes.in
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.2%Here's What Happened - MarketBeat
Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a 72% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Guidance Update: Will Rapport Therapeutics Inc stock continue dividend increasesBull Run & AI Optimized Trade Strategies - moha.gov.vn
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Rapport Therapeutics Inc (RAPP) 財務データ
Rapport Therapeutics Inc (RAPP) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Rapport Therapeutics Inc (RAPP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer |
Jan 20 '26 |
Sale |
26.11 |
5,083 |
132,737 |
25,812 |
| Bredt David | Chief Scientific Officer |
Jan 15 '26 |
Sale |
26.84 |
8,500 |
228,132 |
395,575 |
4.38%
1.95%
大文字化:
|
ボリューム (24 時間):